BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Toth Financial Advisory Corp

Toth Financial Advisory Corp boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 2,878.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,105 shares of the biotechnology company's stock after purchasing an additional 5,900 shares during the period. Toth Financial Advisory Corp's holdings in BioMarin Pharmaceutical were worth $432,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Oregon Public Employees Retirement Fund lifted its holdings in shares of BioMarin Pharmaceutical by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock worth $2,546,000 after purchasing an additional 164 shares during the period. Freedom Investment Management Inc. lifted its stake in BioMarin Pharmaceutical by 3.8% during the 4th quarter. Freedom Investment Management Inc. now owns 5,022 shares of the biotechnology company's stock valued at $330,000 after acquiring an additional 184 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of BioMarin Pharmaceutical by 71.2% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 218 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of BioMarin Pharmaceutical by 64.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 233 shares during the period. Finally, Metis Global Partners LLC increased its stake in shares of BioMarin Pharmaceutical by 4.3% in the fourth quarter. Metis Global Partners LLC now owns 5,686 shares of the biotechnology company's stock worth $374,000 after acquiring an additional 236 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Up 1.1%

BioMarin Pharmaceutical stock traded up $0.60 during trading on Tuesday, hitting $57.48. The company's stock had a trading volume of 1,709,447 shares, compared to its average volume of 1,876,861. The stock has a market capitalization of $11.02 billion, a price-to-earnings ratio of 26.13, a P/E/G ratio of 0.61 and a beta of 0.19. BioMarin Pharmaceutical Inc. has a 1-year low of $52.93 and a 1-year high of $94.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The stock's fifty day moving average is $59.40 and its 200 day moving average is $64.21.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Wedbush restated an "outperform" rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Citigroup lowered their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Bank of America lifted their price target on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Finally, UBS Group boosted their price target on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $93.45.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now owns 16,955 shares in the company, valued at $1,212,621.60. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 3,354 shares of company stock valued at $216,269. Insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.